A french biotech start-up dedicated to the development of muscle secretome-based biotherapies to cure type 1 (T1D) & type 2 (T2D) diabetes is interested to develop breakthrough therapies. Main objective is to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure, heart attack and so on. Partners specialized in T1D, stem-cells, immune modulating specialists, bioproduction, biomarker analysis, are sought under technological and/or R&D agreement.
TRFR20251009013
A french start-up, young spin-off from at the European Center of Diabetes (CeeD) which has more than 30 years of expertise in this field, is developing first-in-class biotherapies derived from the muscle secretome to treat diabetes and other metabolic diseases (NASH, obesity, etc.).
They are a preclinical stage biopharmaceutical company dedicated to developing of first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach.
Their research activites focus on achieving the first functional cure for T1D by enhancing beta cell replacement therapies (pancreatic islet or stem cell transplant). The innovation is a unique combination of pre- and post-transplant treatments based on their product, ensuring better islet survival at every step of the transplant, limiting graft rejection and enhancing its potency in the long term.
The team combines expertises in endocrinology, metabolic diseases, islet isolation process for grafts, pharmacology, molecular biology, biochemistry, primary cell cultures and cell lines (pancreatic cells, adipocytes, etc.).
Advantages and innovations
Within the framework of co-development or EU project, the company is highly interested to contribute to the development of T1D functionnal cure to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure or heart stroke, which causes patients to endure expensive and debilitating treatments and reduces their life expectancy
Technical Specification or Expertise Sought
The company is searching for ppartners from pharmaceutical companies, SME, academia, hospitals from medical and health sectors with specialization in:
- T1D,
- Stem-cells manufacturing,
- Immune modulating specialists,
- Bioproduction,
- Biomarker analysis.
The company is also interested by European projects.
- Type: pharmaceutical companies, SME, academia, hospitals, patient organisations, healthcare providers, policy makers
- Role: technological partners, R&D partners, project coordinator,
- Task(s) to be done:
* Contribution to the development and co-development of new of breakthrough therapies in Type 1 Diabetes (T1D) or in Type 2 Diabetes (T2D)
* Contribution to the work packages writing and implementation in case of European projects